Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival.

Key Points

• The study aims to assess the treatment patterns and survival of myelofibrosis patients treated with ruxolitinib and compare outcomes based on baseline anemia.
• Retrospective analysis of deidentified patient data from the US Flatiron Health electronic health records.
• Focus on patients with myelofibrosis who received ruxolitinib, categorizing them based on anemia status.
• Comparison of treatment doses and survival outcomes between anemic and nonanemic patients.
• Anemic patients received lower doses of ruxolitinib (<20 mg/day) more frequently than nonanemic patients (25% vs 16%).
• Baseline anemic patients had shorter times to first dose reduction (5.6 months vs 12.8 months) and discontinuation (16.7 months vs 24.8 months).
• Median survival was significantly shorter for anemic patients compared to nonanemic patients (37.4 vs 64.9 months, p < .001).
• Patients with worsening anemia on ruxolitinib had significantly worse survival (HR, 1.68, p < .01).